Seegene ranks first in the KOSDAQ market with KRW 268.6 billion
Among the listed corporation whose closing account is at the end of December in the first half, Seegene ranked in the top 100 in operating profit with three major bio companies.
Based on FnGuide’s data, only four of 149 pharmaceutical manufactures recorded more than KRW 100 billion in half-year operating profit among 2,100 manufactures (KOSPI and KOSDAQ market).
Celltrion ranked 32nd with an operating profit of KRW 337.2 billion in the first half alone. Seegene placed 37th with KRW 268.6 billion and entered the top 40.
In particular, Seegene was the only company in the KOSDAQ market to record an operating profit of over KRW 200 billion. During this period, only five KOSDAQ-listed companies made operating profits of more than KRW 100 billion, including Seegene, CJ ENM, LX Semicon, Wonik IPS, and SeoHee Construction.
While Celltrion and Seegene ranked the top 40 in operating profit, Samsung Biologics entered the top 50 by 41st place with KRW 240.7 billion.
SK Bioscience also surpassed KRW 100 billion with KRW 119.9 billion, ranking 70th, and the three major bio companies were placed in the top 100.
Following the four companies that entered the top 100 with an operating profit of over KRW 100 billion, Chong Kun Dang Pharmaceutical ranked 135th with KRW 56.1 billion.
Kolmar BNH ranked 150th with KRW 48.8 billion, Daewoong Pharmaceutical 155th with KRW 46.9 billion, Yuhan Corporation 178th with KRW 40.8 billion, and Hugel 181st with KRW 40.4 billion, entering the top 200.
Between the 200th and 300th, KOSDAQ-listed companies were predominant.
Starting with DongKook Pharmaceutical in 216th place, Bioneer (222nd), Boditech Med (249th), Celltrion Pharm (257th), Pharma Research Products (267th), Huons (268th), Humasis (275th), and Genolution (278th) were listed in the top 300 among KOSDAQ-listed firms, followed by Boryung Pharmaceutical (287th) and Hanmi Pharmaceutical (294th).
Between the 300th and 400th, there were 6 KOSPI-listed companies, including Whanin Pharmaceutical (307th), Chong Kun Dang Holdings (318th), Samjin Pharmaceutical (356th), Korea United Pharm. (370th), Hana Pharm (379th), and Kwang Dong Pharmaceutical (386th), and two KOSDAQ-listed firms, HK Inno.N (380th) and Caregen (383rd).
Moreover, JW Lifescience (412th), Daehan New Pharm (432nd), Handok (435th), JW Pharmaceutical (437th), and Daihan Pharmaceutical (449th) entered the top 500 with over KRW 10 billion in operating profit, but Dong Wha Pharm (525th) remained out of the 500th.
Meanwhile, Seegene ranked No.1 in operating profit in the entire KOSDAQ market, but 50 companies, nearly half of 106 medicinal and pharmaceutical products manufactures, posted losses.
Although Seegene alone posted an operating profit of nearly KRW 300 billion, the combined operating profit of 106 companies was only KRW 488.6 billion.
In the KOSPI market, 11 out of 43 medicinal and pharmaceutical products manufactures posted losses, but the combined operating profit was KRW 1.224 trillion, more than double that of the KOSDAQ market.
